Solid Biosciences (SLDB) EBIT: 2017-2024
Historic EBIT for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$39.9 million.
- Solid Biosciences' EBIT fell 79.19% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of -$129.7 million for FY2024, which is 24.44% down from last year.
- Per Solid Biosciences' latest filing, its EBIT stood at -$39.9 million for Q4 2024, which was down 13.40% from -$35.2 million recorded in Q3 2024.
- Solid Biosciences' EBIT's 5-year high stood at -$19.0 million during Q2 2020, with a 5-year trough of -$39.9 million in Q4 2024.
- Over the past 3 years, Solid Biosciences' median EBIT value was -$26.9 million (recorded in 2024), while the average stood at -$28.6 million.
- Per our database at Business Quant, Solid Biosciences' EBIT skyrocketed by 35.59% in 2023 and then plummeted by 79.19% in 2024.
- Quarterly analysis of 4 years shows Solid Biosciences' EBIT stood at -$21.3 million in 2020, then reached -$34.6 million in 2022, then skyrocketed by 35.59% to -$22.3 million in 2023, then tumbled by 79.19% to -$39.9 million in 2024.
- Its EBIT stands at -$39.9 million for Q4 2024, versus -$35.2 million for Q3 2024 and -$27.8 million for Q2 2024.